TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Recruiting · NCT05188313 · Registry updated 2022-06-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, esophageal cancer, esophageal disorder, neoplasm | Recruiting | Phase 3 | 2022-06-24 | NCT05188313 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 199 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Academic Medical Center | Amsterdam | Netherlands | 5 |